GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK), a leading UK pharmaceutical company, last week announced positive results from a Phase III clinical trial for gepotidacin, a first-in-class triazaacenaphthylene antibiotic, in the treatment of uncomplicated urogenital gonorrhoea (GC). The study demonstrated non-inferiority to the standard azithromycin-based treatment, with a microbiological response rate of 92.6% for gepotidacin compared to 91.2% in the control group. The safety and tolerability profile of the drug was found to be consistent with previous phase findings.
Gepotidacin is a novel bactericidal agent designed to inhibit two type II topoisomerase enzymes that are prevalent in a range of pathogens, including those resistant to existing antibiotic treatments. This molecule is also currently in Phase III of development for the treatment of uncomplicated urinary tract infections (uUTI).- Flcube.com
